Last reviewed · How we verify
Gammanorm
At a glance
| Generic name | Gammanorm |
|---|---|
| Sponsor | Octapharma |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Subcutaneous Immunoglobulin for Myasthenia Gravis (PHASE2)
- The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency
- Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases
- A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push (PHASE4)
- Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps (PHASE4)
- Immunoglobulin Dosage and Administration Form in CIDP and MMN
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |